前立腺癌診断の世界市場 (2023年～2028年)：規模・予測・産業動向・成長・シェア・展望・インフレの影響・機会・企業分析

世界の前立腺癌診断の市場規模は、2022年の36億6,000万米ドルから、予測期間中は14.50%のCAGRで推移し、2028年には82億5,000万米ドルの規模に成長すると予測されています。

予測期間中は前立腺癌を患うリスクのある高齢者人口の増加が、市場成長を後押しするものと思われます。前立腺癌は、世界で最も多い非皮膚癌です。先進国の人々の座りがちなライフスタイルや、泌尿器科疾患の早期発症が、前立腺癌の世界の有病率を押し上げています。

当レポートでは、世界の前立腺癌診断の市場を調査し、市場概要、促進要因と課題、市場規模の推移・予測、各種区分・地域別の内訳、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査・手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因
• 課題

第5章 ポーターのファイブフォース分析

第6章 世界の前立腺癌診断市場

第7章 市場シェア：世界の前立腺癌診断市場

• 検査別
• 検査タイプ別
• 地域別
• エンドユーザー別

第8章 世界の前立腺癌診断市場：検査別

• 予備検査
• 確認検査

第9章 世界の前立腺癌診断市場：検査タイプ別

• PSA3 TESR
• 経直腸超音波
• 生検

第10章 世界の前立腺癌診断市場：地域別

• 北欧
• 西欧
• カリブ海
• オーストラリア
• 北米
• 南アフリカ
• 南米
• 南欧州
• ミクロネシア
• 東欧
• 中米
• 中央アフリカ
• メラネシア
• 西アフリカ
• 西アジア
• 東アフリカ
• 東アジア
• 北アフリカ
• 東南アジア
• 南中央アジア

第11章 世界の前立腺癌診断市場：エンドユーザー別

• 病院・診療所
• 診断センター
• 研究機関
• その他

第12章 主要企業の分析

• Thermo Fisher Scientific
• Myriad Genetics, Inc.
• Abbott Laboratories
• F.Hoffman-La Roche AG
• Siemens Healthineer AG
• OPKO Health Inc.
• Astra Zeneca
• Bayer AG
• Sanofi Avantis
• Hologic Inc

List of Figures

• Figure-01: Global - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-02: Global - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-03: Type - Preliminary Test Market (Million US$), 2018 - 2022
• Figure-04: Type - Forecast for Preliminary Test Market (Million US$), 2023 - 2028
• Figure-05: Type - Confirmatory Test Market (Million US$), 2018 - 2022
• Figure-06: Type - Forecast for Confirmatory Test Market (Million US$), 2023 - 2028
• Figure-07: Test Type - PSA3 TESR Market (Million US$), 2018 - 2022
• Figure-08: Test Type - Forecast for PSA3 TESR Market (Million US$), 2023 - 2028
• Figure-09: Test Type - Transrectal Ultrasound Market (Million US$), 2018 - 2022
• Figure-10: Test Type - Forecast for Transrectal Ultrasound Market (Million US$), 2023 - 2028
• Figure-11: Test Type - Biopsy Market (Million US$), 2018 - 2022
• Figure-12: Test Type - Forecast for Biopsy Market (Million US$), 2023 - 2028
• Figure-13: North Europe - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-14: North Europe - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-15: North Europe - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-16: North Europe - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-17: Western Europe - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-18: Western Europe - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-19: Western Europe - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-20: Western Europe - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-21: Carribean - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-22: Carribean - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-23: Carribean - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-24: Carribean - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-25: Australia - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-26: Australia - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-27: Australia - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-28: Australia - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-29: North America - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-30: North America - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-31: North America - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-32: North America - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-33: South Africa - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-34: South Africa - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-35: South Africa - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-36: South Africa - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-37: South America - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-38: South America - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-39: South America - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-40: South America - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-41: South Europe - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-42: South Europe - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-43: South Europe - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-44: South Europe - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-45: Micronesia - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-46: Micronesia - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-47: Micronesia - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-48: Micronesia - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-49: Eastern Europe - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-50: Eastern Europe - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-51: Eastern Europe - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-52: Eastern Europe - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-53: Central America - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-54: Central America - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-55: Central America - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-56: Central America - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-57: Middle Africa - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-58: Middle Africa - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-59: Middle Africa - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-60: Middle Africa - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-61: Melasnesia - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-62: Melasnesia - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-63: Melasnesia - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-64: Melasnesia - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-65: Western Africa - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-66: Western Africa - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-67: Western Africa - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-68: Western Africa - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-69: Western Asia - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-70: Western Asia - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-71: Western Asia - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-72: Western Asia - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-73: Eastern Africa - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-74: Eastern Africa - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-75: Eastern Africa - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-76: Eastern Africa - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-77: Eastern Asia - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-78: Eastern Asia - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-79: Eastern Asia - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-80: Eastern Asia - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-81: North Africa - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-82: North Africa - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-83: North Africa - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-84: North Africa - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-85: South East Asia - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-86: South East Asia - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-87: South East Asia - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-88: South East Asia - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-89: South Central Asia - Prostate Cancer Diagnostic Volume (Total no. of Cases), 2018 - 2022
• Figure-90: South Central Asia - Forecast for Prostate Cancer Diagnostic Volume (Total no. of Cases), 2023 - 2030
• Figure-91: South Central Asia - Prostate Cancer Diagnostic Market (Billion US$), 2018 - 2022
• Figure-92: South Central Asia - Forecast for Prostate Cancer Diagnostic Market (Billion US$), 2023 - 2028
• Figure-93: End User - Hospital and clinics Market (Million US$), 2018 - 2022
• Figure-94: End User - Forecast for Hospital and clinics Market (Million US$), 2023 - 2028
• Figure-95: End User - Diagnostic centers Market (Million US$), 2018 - 2022
• Figure-96: End User - Forecast for Diagnostic centers Market (Million US$), 2023 - 2028
• Figure-97: End User - Research Institutes Market (Million US$), 2018 - 2022
• Figure-98: End User - Forecast for Research Institutes Market (Million US$), 2023 - 2028
• Figure-99: End User - Others Market (Million US$), 2018 - 2022
• Figure-100: End User - Forecast for Others Market (Million US$), 2023 - 2028
• Figure-101: Thermo Fisher Scientific - Global Revenue (Billion US$), 2018 - 2022
• Figure-102: Thermo Fisher Scientific - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-103: Myriad Genetics, Inc. - Global Revenue (Billion US$), 2018 - 2022
• Figure-104: Myriad Genetics, Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-105: Abbott Laboratories - Global Revenue (Billion US$), 2018 - 2022
• Figure-106: Abbott Laboratories - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-107: F.Hoffman-La Roche AG - Global Revenue (Billion US$), 2018 - 2022
• Figure-108: F.Hoffman-La Roche AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-109: Siemens Healthineer AG - Global Revenue (Billion US$), 2018 - 2022
• Figure-110: Siemens Healthineer AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-111: OPKO Health Inc. - Global Revenue (Billion US$), 2018 - 2022
• Figure-112: OPKO Health Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-113: Astra Zeneca - Global Revenue (Billion US$), 2018 - 2022
• Figure-114: Astra Zeneca - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-115: Bayer AG - Global Revenue (Billion US$), 2018 - 2022
• Figure-116: Bayer AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-117: SanofiAvantis - Global Revenue (Billion US$), 2018 - 2022
• Figure-118: SanofiAvantis - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-119: Hologic Inc - Global Revenue (Billion US$), 2018 - 2022
• Figure-120: Hologic Inc - Forecast for Global Revenue (Billion US$), 2023 - 2028

List of Tables

• Table-01: Global - Prostate Cancer Diagnostic Market Share by Test (Percent), 2018 - 2022
• Table-02: Global - Forecast for Prostate Cancer Diagnostic Market Share by Test (Percent), 2023 - 2028
• Table-03: Global - Prostate Cancer Diagnostic Market Share by Test Type (Percent), 2018 - 2022
• Table-04: Global - Forecast for Prostate Cancer Diagnostic Market Share by Test Type (Percent), 2023 - 2028
• Table-05: Global - Prostate Cancer Diagnostic Market Share by Region (Percent), 2018 - 2022
• Table-06: Global - Forecast for Prostate Cancer Diagnostic Market Share by Region (Percent), 2023 - 2028
• Table-07: Global - Prostate Cancer Diagnostic Market Share by End User (Percent), 2018 - 2022
• Table-08: Global - Forecast for Prostate Cancer Diagnostic Market Share by End User (Percent), 2023 - 2028

Global Prostate Cancer Diagnostics Market will be US$ 8.25 Billion by 2028 compared to US$ 3.66 Billion in 2022. Prostate cancer is the most frequent kind of cancer and one of the top causes of cancer mortality among people of all races and Hispanic origin. According to Globocan 2020, the global prevalence of prostate cancer was 1,414,259 cancer cases. According to the United Nations' World Population 2022 report, the proportion of the world population aged 65 and over is expected to climb from 10% in 2022 to 16% in 2050. Over the projected period, an increase in the senior population at risk of acquiring prostate cancer is likely to boost market growth.

Global Prostate Cancer Diagnostics Industry is expected to grow with a double-digit staggering CAGR of 14.50% during 2022-2028

Prostate cancer is the most common non-cutaneous cancer worldwide. The sedentary lifestyle of people in industrialized nations as well as the early start of urological problems, are driving the global prevalence of prostate cancer. Major advancements in prostate cancer diagnostics have occurred in the previous decade, with increased product approvals and innovations likely to contribute to the expansion of the investigated market. For example, in March 2022, the US Food and Drug Administration authorized Novartis' Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. As a result, higher acceptance of prostate cancer medicines will drive the market growth.

Preliminary Test Segment is expected to hold the Largest Market Share over the Forecast Period

Due to an increase in the frequency of prostate cancer, preliminary tests accounted for a significant share of the market. The easy availability of PSA screening, according to the American Institute for Cancer Research, has aided early detection and treatment, enhancing survival rates. Furthermore, PSA testing discovers unidentified and tiny tumours that may or may not progress to an advanced cancer stage. These tests are suggested to most men over 50 and those at risk of acquiring the condition since they allow for identification before serious symptoms arise.

The rise in product approvals by the Food and Drug Administration (FDA) is expected to fuel market growth over the forecast period. For instance, the United States Food and Drug Administration (FDA) will approve Novartis' Lu-PSMA-617 in March 2022. It is a radiopharmaceutical treatment for prostate cancer.

Prostate Cancer Antigen 3 (PCA3) Test Market is anticipated to attain Substantial Growth by the end of the Forecast Period

Prostate Cancer is classified into three types of tests: PCA3 TEST, Transrectal Ultrasound, and Biopsy. The prostate cancer antigen 3 (PCA3) test market is expected to grow significantly in developing economies during the forecast period, owing to factors such as rising demand for early detection and a better diagnostic system, rising prevalence of prostate cancer, and an increase in the number of research activities, all of which will contribute to market growth.

The worldwide transrectal ultrasound market is expanding due to a rise in the prevalence and incidence rates of prostate cancer. Furthermore, the increased uses of imaging systems in healthcare facilities, as well as the introduction of new and technologically sophisticated systems into the market, are likely to drive demand for transrectal ultrasound systems throughout the forecast period. Furthermore, high diagnosis rates of benign prostatic hyperplasia, an increase in the frequency of urological illnesses, and an increase in demand for transrectal ultrasonography treatments in Europe are significant drivers driving transrectal ultrasound market expansion.

Growing Older Populations, as well as the shift from non-communicable to Communicable Illnesses, are Driving Growth in the Diagnostics Center Industry

End-users are classified as Hospitals & Clinics, Diagnostics Centers, Research Institutes, and Others. The Diagnostics Centers sector held the most market share. The rising number of patients visiting diagnostics centers, the increasing number of in-house diagnostics procedures conducted, and the growing awareness of the need of early diagnosis are the primary driving forces in this market.

The need for preventative and curative healthcare will increase by 2023. Innovative technology, such as robotic process automation, has arisen as a natural answer at high-end diagnostics centers, along with digitalization, to fill skill gaps in lab technicians and employees, as well as it increases precision and speed of results. To support these advancements, modern technology and tools have had a very beneficial influence on the diagnostics services industry.

North America will lead in Prostate Cancer Diagnostics Market in upcoming Years

Based on Region, the prostate cancer diagnostics market are segmented into Northern Europe, Western Europe, South Europe, Eastern Europe, Micronesia, Melanesia, North America, South America, Central America, Middle Africa, Western Africa, Eastern Africa, North Africa, South Africa South central Asia, Southeast Asia, Eastern Asia, Western Asia, Australia and Caribbean. The increased prevalence of prostate cancer in the United States is predicted to fuel growth in the prostate cancer testing market in the United States. Furthermore, corporate leaders are focusing on developing a thorough grasp of the prostate cancer industry in order to fulfill unmet requirements in clinical research.

Asia-Pacific nations are predicted to expand at the fastest CAGR during the forecast period, as the demand for prostate cancer diagnostics products is growing rapidly due to urbanization. China is predicted to lead the Asia-Pacific prostate cancer diagnostics market due to its big population and hence greater total number of tests than other countries in the area.

Competitive Landscape

The major companies providing Asia-Pacific prostate cancer diagnostics market report are: Myriad Genetics, Inc., Abbott Laboratories, F. Hoffman-La Roche AG, Siemens Healthiness AG, OPKO Health, Inc., AstraZeneca, Bayer AG, Sanofi-Aventis, Thermo Fisher Scientific, Hologic, Inc. among other domestic players.

RSIP Vision offered a new prostate MRI-to-ultrasound registration technology in May 2021, which allows MRI-to-ultrasound registration utilizing regular MRI scans and trans-rectal ultrasound pictures.

Paige got USFDA permission in September 2021 for the de novo sale of PaigeProsate, a clinical-grade AI system for prostate cancer diagnosis.

Myovant teamed with Pfizer in January 2021 to sell their prostate cancer medicine Orgovyx (relugolix), which was authorized in December 2020.

Renub Research latest report "Prostate Cancer Diagnostics Market Global Forecast by Diagnosis Type (preliminary test and confirmatory test), Test Type (PCA3, Trans-rectal Ultrasound, Biopsy), End Users (Hospitals & Clinics, Diagnostics Centers, Research Institute, Others), Regions (Northern Europe, Western Europe, South Europe, Eastern Europe, Micronesia, Melanesia, North America, South America, Central America, Middle Africa, Western Africa, Eastern Africa, North Africa, South Africa South central Asia, Southeast Asia, Eastern Asia, Western Asia, Australia and Caribbean), Company Analysis (Myriad Genetics, Inc., Abbott Laboratories, F. Hoffman-La Roche AG, Siemens Healthiness AG, OPKO Health, Inc., AstraZeneca, Bayer AG, Sanofi-Aventis, Thermo Fisher Scientific, Hologic, Inc.)" provides a complete analysis of Prostate Cancer Diagnostics Industry.

Diagnosis Type - Market breakup from 2 viewpoints

• 1. Preliminary Screening Test
• 2. Confirmatory Test

Test Type - Market breakup from 3 viewpoints

• 1. PCA3
• 2. Trans-rectal Ultrasound
• 3. Biopsy

End-Users - Market breakup from 4 viewpoints

• 1. Hospitals& Clinics
• 2. Diagnostic Centers
• 3. Research institute
• 4. Others

Regions - Market breakup by 20 Countries

• 1. Northern Europe
• 2. Western Europe
• 3. South Europe
• 4. Eastern Europe
• 5. Micronesia
• 6. Melanesia
• 7. North America
• 8. South America
• 9. Central America
• 10. Middle Africa
• 11. Western Africa
• 12. Eastern Africa
• 13. North Africa
• 14. South Africa
• 15. South central Asia
• 16. Southeast Asia
• 17. Eastern Asia
• 18. Western Asia
• 19. Australia
• 20. Caribbean

All companies have been covered with 3 viewpoints

• Overviews
• Recent Developments
• Revenues

Company Analysis:-

• 1. Myriad Genetics, Inc.
• 2. Abbott Laboratories
• 3. F. Hoffman-La Roche AG
• 4. Siemens Healthiness AG
• 5. OPKO Health, Inc.
• 6. AstraZeneca
• 7. Bayer AG
• 8. Sanofi-Aventis
• 9. Thermo Fisher Scientific
• 10. Hologic, Inc

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenge

5. Porters Five Forces

• 5.1 Competitive Rivalry
• 5.2 Supplier Power
• 5.3 Buyer Power
• 5.4 Threat of Substitution
• 5.5 Threat of New Entry

6. Global Prostate Cancer Diagnostic Market

7. Market Share - Global Prostate Cancer Diagnostic Analysis

• 7.1 By Test
• 7.2 By Test Type
• 7.3 By Region
• 7.4 By End User

8. Test - Global Prostate Cancer Diagnostic Market

• 8.1 Preliminary Test
• 8.2 Confirmatory Test

9. Test Type - Global Prostate Cancer Diagnostic Market

• 9.1 PSA3 TESR
• 9.2 Transrectal Ultrasound
• 9.3 Biopsy

10. Region - Global Prostate Cancer Diagnostic Market

• 10.1 North Europe
  • 10.1.1 Total no. of Cases
  • 10.1.2 Market
• 10.2 Western Europe
  • 10.2.1 Total no. of Cases
  • 10.2.2 Market
• 10.3 Carribean
  • 10.3.1 Total no. of Cases
  • 10.3.2 Market
• 10.4 Australia
  • 10.4.1 Total no. of Cases
  • 10.4.2 Market
• 10.5 North America
  • 10.5.1 Total no. of Cases
  • 10.5.2 Market
• 10.6 South Africa
  • 10.6.1 Total no. of Cases
  • 10.6.2 Market
• 10.7 South America
  • 10.7.1 Total no. of Cases
  • 10.7.2 Market
• 10.8 South Europe
  • 10.8.1 Total no. of Cases
  • 10.8.2 Market
• 10.9 Micronesia
  • 10.10.1 Total no. of Cases
  • 10.10.2 Market
• 10.10 Eastern Europe
  • 10.10.1 Total no. of Cases
  • 10.10.2 Market
• 10.11 Central America
  • 10.12.1 Total no. of Cases
  • 10.12.2 Market
• 10.12 Middle Africa
  • 10.12.1 Total no. of Cases
  • 10.12.2 Market
• 10.13 Melasnesia
  • 10.13.1 Total no. of Cases
  • 10.13.2 Market
• 10.14 Western Africa
  • 10.14.1 Total no. of Cases
  • 10.14.2 Market
• 10.15 Western Asia
  • 10.15.1 Total no. of Cases
  • 10.15.2 Market
• 10.16 Eastern Africa
  • 10.16.1 Total no. of Cases
  • 10.16.2 Market
• 10.17 Eastern Asia
  • 10.17.1 Total no. of Cases
  • 10.17.2 Market
• 10.18 North Africa
  • 10.18.1 Total no. of Cases
  • 10.18.2 Market
• 10.19 South East Asia
  • 10.110.1 Total no. of Cases
  • 10.110.2 Market
• 10.20 South Central Asia
  • 10.20.1 Total no. of Cases
  • 10.20.2 Market

11. End User - Global Prostate Cancer Diagnostic Market

• 11.1 Hospital and clinics
• 11.2 Diagnostic centers
• 11.3 Research Institutes
• 11.4 Others

12. Key Players Analysis

• 12.1 Thermo Fisher Scientific
  • 12.1.1 Business Overview
  • 12.1.2 Sales Analysis
  • 12.1.3 Recent Development
• 12.2 Myriad Genetics, Inc.
  • 12.2.1 Business Overview
  • 12.2.2 Sales Analysis
  • 12.2.3 Recent Development
• 12.3 Abbott Laboratories
  • 12.3.1 Business Overview
  • 12.3.2 Sales Analysis
  • 12.3.3 Recent Development
• 12.4 F.Hoffman-La Roche AG
  • 12.4.1 Business Overview
  • 12.4.2 Sales Analysis
  • 12.4.3 Recent Development
• 12.5 Siemens Healthineer AG
  • 12.5.1 Business Overview
  • 12.5.2 Sales Analysis
  • 12.5.3 Recent Development
• 12.6 OPKO Health Inc.
  • 12.6.1 Business Overview
  • 12.6.2 Sales Analysis
  • 12.6.3 Recent Development
• 12.7 Astra Zeneca
  • 12.7.1 Business Overview
  • 12.7.2 Sales Analysis
  • 12.7.3 Recent Development
• 12.8 Bayer AG
  • 12.8.1 Business Overview
  • 12.8.2 Sales Analysis
  • 12.8.3 Recent Development
• 12.9 Sanofi Avantis
  • 12.9.1 Business Overview
  • 12.9.2 Sales Analysis
  • 12.9.3 Recent Development
• 12.10 Hologic Inc
  • 12.10.1 Business Overview
  • 12.10.2 Sales Analysis
  • 12.10.3 Recent Development